StreetInsider.com News Articles

Insmed to Present at September 2026 Investor Conferences

Wed, 26 Aug 2026 07:00:00 -0400

BRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences:

12th Annual Cantor Fitzgerald Global Healthcare Conference in New York City on Wednesday, September 9, 2026, at 8:00 a.m. ET.
24th Annual Morgan Stanley Global Healthcare Conference in New York City on Monday, September 14, 2026, at 2:35 p.m. ET.

These events will be

Insmed to Present at September 2026 Investor Conferences

Wed, 26 Aug 2026 07:00:00 -0400

12th Annual Cantor Fitzgerald Global Healthcare Conference in New York City on Wednesday, September 9, 2026, at 8:00 a.m. ET.
24th Annual Morgan Stanley Global Healthcare Conference in New York City on Monday, September 14, 2026, at 2:35 p.m. ET.

These events will be

Insmed to Present at September 2026 Investor Conferences

Wed, 26 Aug 2026 07:00:00 -0400

12th Annual Cantor Fitzgerald Global Healthcare Conference in New York City on Wednesday, September 9, 2026, at 8:00 a.m. ET.
24th Annual Morgan Stanley Global Healthcare Conference in New York City on Monday, September 14, 2026, at 2:35 p.m. ET.

These events will be

Insmed to Present at September 2026 Investor Conferences

Wed, 26 Aug 2026 07:00:00 -0400

12th Annual Cantor Fitzgerald Global Healthcare Conference in New York City on Wednesday, September 9, 2026, at 8:00 a.m. ET.
24th Annual Morgan Stanley Global Healthcare Conference in New York City on Monday, September 14, 2026, at 2:35 p.m. ET.

These events will be

Form 4 INSMED Inc For: Aug 17 Filed by: SHAROKY MELVIN MD

Tue, 25 Aug 2026 19:03:00 -0400

si-local-file:///var/storage/secattach/20260825/26975988.html

Form 4 INSMED Inc For: Aug 17 Filed by: SHAROKY MELVIN MD

Tue, 25 Aug 2026 19:03:00 -0400

si-local-file:///var/storage/secattach/20260825/26975988.html

Insmed (INSM) PT Raised to $195 at Mizuho

Mon, 24 Aug 2026 15:37:30 -0400

Mizuho analyst Graig Suvannavejh raised the price target on Insmed (NASDAQ: INSM) to $195.00 (from $192.00) while maintaining a Outperform rating.

The analyst comments "This morning, INSM announced Japanese approval of Brinsupri for non-cystic fibrosis bronchiectasis/NCFBE in adults and pediatric patients 12 years and older. As a result, with our probability-of-success/POS assumption for Brinsupri in Japan increasing to 100 from 90%, we raise our 12-month price target on INSM to $195 from $192, implying 55% upside. Bigger picture on INSM, since the company reported a positive 2Q26 revenue beat for Brinsupri back on August 6 (LINK), and concurrently announced guidance raises

Insmed (INSM) PT Raised to $195 at Mizuho

Mon, 24 Aug 2026 15:37:30 -0400

Mizuho analyst Graig Suvannavejh raised the price target on Insmed (NASDAQ: INSM) to $195.00 (from $192.00) while maintaining a Outperform rating.

Japan approves Insmed's Brinsupri for lung disease treatment

Mon, 24 Aug 2026 07:03:17 -0400

Insmed Incorporated (Nasdaq: INSM) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Brinsupri (brensocatib 25-mg tablet), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12 years and older.

The approval, based on results from the Phase 3 ASPEN study, makes Brinsupri the first MHLW-approved treatment for NCFB. The drug is now approved in the U.S., Europe, and Japan.

In the ASPEN study, brensocatib significantly reduced pulmonary exacerbations compared with placebo over a 52-week treatment period. The study also met multiple key secondary endpoints, including significantly prolonging the time to first exacerbation and

Japan approves Insmed's Brinsupri for lung disease treatment

Mon, 24 Aug 2026 07:03:17 -0400

The approval, based on results from the Phase 3 ASPEN study, makes Brinsupri the first MHLW-approved treatment for NCFB. The drug is now approved in the U.S., Europe, and Japan.

BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Mon, 24 Aug 2026 07:00:00 -0400